http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c62142707ff04d14c1ea521a18015bc3
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Matulonis |
| name | Ursula A Matulonis Ursula A. Matulonis |
| given-name | Ursula A. Ursula A |
| organization-name | 2Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital; From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL Division of Hematology/Oncology, Department of Medical Oncology Dana Farber Cancer Institute Boston MA From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women’s Hospital; Division of Hematology/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA. 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 13Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts; Harvard Medical School Boston Massachusetts From the Dana-Farber Cancer Institute; Harvard Medical School; and Brigham and Women's Hospital, Boston, MA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O’Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M... From the Dana-Farber/Harvard Cancer Center; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center, Boston, MA; and Women and Infants' Hospital, Providence, RI. 3Department of Medical Oncology, Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Division of Gynecologic Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, United States of America Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts. Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts Department of Medical Oncology Dana-Farber Cancer Institute Boston MA Gynecologic Oncology, Dana Farber Cancer Institute, Boston, MA Authors' Affiliations: Departments of 1Cancer Biology, 2Biostatistics and Computational Biology, and 3Medical Oncology, Dana-Farber Cancer Institute; 4Department of Pathology and 5Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts; 6Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark; 7Cancer Genomics Program, Departments of 8Biochemistry and 9Pathology, and 10Familial Cancer Centre, Peter MacCallum Cancer Centre and the University of Melbourne, Parkville, Melbourne, Victoria; 11Department of Gynaecological Oncology and Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia; 12Department of Obstetrics and Gynecology, Haukeland University Hospital; and 13Department of Clinical Medicine, University of Bergen, Bergen, Norway 9Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; 10Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Alexi A. Wright, Angel Cronin, Dana E. Milne, Nancy L. Keating, Ursula A. Matulonis, and Jane C. Weeks, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Michael A. Bookman, University of Arizona Cancer Center, Tucson, AZ; Robert A. Burger, University of Pennsylvania; Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA; David E. Cohn and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mihaela Cristea and Joyce C. Niland, City of Hope... Department of Medical Oncology, Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School 5Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts. Dana‐Farber Cancer Institute Boston Massachusetts Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts From the Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Hematology and Oncology and Biostatistics Center, Massachusetts General Hospital; Division of Gynecologic Oncology and Department of Medicine, Brigham and Women's Hospital; Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston; Department of Hematology and Oncology, Lahey Clinic, Burlington; Wyeth Pharmaceuticals, Cambridge MA; and Cancer Therapy Evaluation Program, National Cancer Institute... 1Dana Farber Cancer Institute, Boston Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 Department of Medical Oncology Dana Farber Cancer Institute Boston Massachusetts Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brooklyn Avenue, Boston, MA 02215, USA. From the Arizona Cancer Center, Tuscon and Scottsdale, AZ; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber/Harvard Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Sarah Cannon Research Institute, Nashville, TN; Cedars-Sinai Medical Center; UCLA Medical Center, Los Angeles, CA; USC Norris Comprehensive Cancer Center; Genentech Inc, South San Francisco, CA; Fox Chase Cancer Center; James Cancer Hospital, Ohio State University,... Gynecologic Oncology Program Dana‐Farber Cancer Institute Boston Massachusetts 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Larissa A. Meyer, Charlotte C. Sun, and Charles F. Levenback, The University of Texas MD Anderson Cancer Center, Houston, TX; Angel M. Cronin, Ursula A. Matulonis, and Alexi A. Wright, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA; Kristin Bixel and David M. O’Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Michael A. Bookman, US Oncology Research and Arizona Oncology, Tucson, AZ; Mihaela C. Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center,... Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts. 6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 7Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 1Dana-Farber Cancer Institute, Boston, Massachusetts. Division of Gynecologic Oncology, Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA Elizabeth H. Stover, Ursula A. Matulonis, and Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School; and Colleen Feltmate, Ross S. Berkowitz, and Neal I. Lindeman, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. From Northwestern University (D. Matei) and Loyola University (W.S.) — both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island–The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers... Department of Hematology Oncology, Dana-Farber Cancer Institute , Boston, MA , USA Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts Dana-Farber Cancer Institute, Boston, MA, USA, Harvard Medical School, Boston, MA, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States 2Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Dana-Farber Cancer Institute, Boston, Massachusetts Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 4Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA |
Incoming Links
Showing number of triples: 1 to 249 of 249.